| # | Drug | Count |
|---|---|---|
| 0 | PACLITAXEL | 111 |
| 1 | PACLITAXEL (AIBUMIN-BOUND) | 111 |
| 2 | TRASTUZUMAB | 106 |
| 3 | OXALIPLATIN | 84 |
| 4 | FLUOROURACIL | 75 |
| 5 | FLUOROURACIL CREAM, 0.5% | 75 |
| 6 | PEMBROLIZUMAB | 49 |
| 7 | CARBOPLATIN | 48 |
| 8 | CYCLOPHOSPHAMIDE | 44 |
| 9 | CYCLOPHOSPHAMIDE FOR INJECTION | 44 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ENSARTINIB | 1 | 0.0222 |
| 1 | COCAINE HYDROCHLORIDE NASAL | 1 | 0.0154 |
| 2 | PECTIN | 1 | 0.0125 |
| 3 | PENPULIMAB | 1 | 0.0102 |
| 4 | LANOLIN, PETROLATUM | 1 | 0.0040 |
| 5 | MILRINONE LACTATE | 1 | 0.0036 |
| 6 | LIFILEUCEL | 1 | 0.0035 |
| 7 | GLUTATHIONE | 6 | 0.0035 |
| 8 | ORITAVANCIN DIPHOSPHATE | 1 | 0.0034 |
| 9 | DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE | 1 | 0.0032 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 138 |
| 1 | Microtubule Inhibitor [EPC] | 121 |
| 2 | HER2/neu Receptor Antagonist [EPC] | 107 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 101 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 79 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 78 |
| 6 | Corticosteroid [EPC] | 77 |
| 7 | Kinase Inhibitor [EPC] | 74 |
| 8 | Alkylating Drug [EPC] | 52 |
| 9 | Opioid Agonist [EPC] | 48 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 1 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 2 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 7 | 0.0017 |
| 3 | Guanylate Cyclase-C Agonist [EPC] | 3 | 0.0014 |
| 4 | HER2/neu Receptor Antagonist [EPC] | 107 | 0.0014 |
| 5 | Benzodiazepine Antagonist [EPC] | 1 | 0.0011 |
| 6 | Gamma Secretase Inhibitor [EPC] | 1 | 0.0011 |
| 7 | CD38-directed Cytolytic Antibody [EPC] | 5 | 0.0009 |
| 8 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 78 | 0.0008 |
| 9 | Alkaloid [EPC] | 20 | 0.0008 |